-+ 0.00%
-+ 0.00%
-+ 0.00%

Natera Reports Signatera MRD Test Predicts Recurrence Risk in Early-Stage HR+/HER2- Breast Cancer

路透·12/11/2025 00:57:15

登录查看新闻详情